Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients

Background Peritoneal dialysis (PD) is an important therapy for patients with end‐stage kidney disease and is used in more than 200,000 such patients globally. However, its value is often limited by the development of infections such as peritonitis and exit‐site and tunnel infections. Multiple strat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cochrane database of systematic reviews 2017-04, Vol.2017 (6), p.CD004679-CD004679
Hauptverfasser:	Campbell, Denise, Mudge, David W, Craig, Jonathan C, Johnson, David W, Tong, Allison, Strippoli, Giovanni FM
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intranasal Administration, Topical Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use Anti-Infective Agents, Local - administration & dosage Anti-Infective Agents, Local - therapeutic use Antibiotic Prophylaxis Antifungal Agents Antifungal Agents - administration & dosage Antifungal Agents - therapeutic use Anti‐Bacterial Agents Anti‐Infective Agents, Local Catheter-Related Infections - epidemiology Catheter-Related Infections - prevention & control Catheter‐Related Infections Child health Device Removal Device Removal - adverse effects END‐STAGE KIDNEY DISEASE Gastroenterology Gastroenterology & hepatology Humans Infection ‐ prevention and treatment Injections, Intravenous Kidney disease Medicine General & Introductory Medical Sciences Mupirocin Mupirocin - administration & dosage Mupirocin - therapeutic use Mycoses Mycoses - prevention & control Other bowel disorders Peritoneal Dialysis Peritoneal Dialysis - adverse effects Peritonitis Peritonitis - epidemiology Peritonitis - prevention & control Randomized Controlled Trials as Topic Vancomycin Vancomycin - administration & dosage Vancomycin - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!